On November 8, 2025 (local time), during the opening session of the American Heart Association (AHA) Scientific Sessions 2025, groundbreaking Phase II clinical data for DR10624 were announced. DR10624 is a globally first-in-class (FIC) long-acting triple-target agonist targeting FGF21R, GCGR, and GLP-1R, developed by Doer Biologics using its proprietary MultipleBody® platform technology. The data were from the "DR10624-201 Study" in patients with severe hypertriglyceridemia (SHTG). Professor Li Jianping, Principal Investigator of the DR10624-201 study, Vice President of Peking University First Hospital, and Director of the Cardiovascular Disease Research Institute, was invited to deliver the opening report at the session titled "Late-Breaking Science: Groundbreaking Trials in Cardiometabolic Therapeutics." The DR10624-201 study demonstrated breakthrough efficacy, achieving a 75% reduction in triglycerides and a 67% reduction in liver fat. This achievement has not only garnered widespread coverage from international mainstream pharmaceutical media but also marks a significant breakthrough for Chinese innovative drugs in the field of metabolic diseases.
The American Heart Association (AHA), founded in 1924, is the largest, longest-standing, and most influential volunteer organization in the field of cardiovascular health worldwide. The AHA Scientific Sessions are a premier international conference showcasing the latest scientific and clinical advancements in cardiovascular diseases, brain health, and related conditions.
Links to some media coverages: Newsroom MedpageToday Healio TCTMD